Down-regulation of protein kinase Cη potentiates the cytotoxic effects of exogenous tumor necrosis factor–related apoptosis-inducing ligand in PC-3 prostate cancer cells
- Jürgen Sonnemann1,
- Volker Gekeler3,
- Antje Sagrauske1,
- Cornelia Müller2,
- Hans-Peter Hofmann3 and
- James F. Beck2
- 1Peter Holtz Research Center of Pharmacology and Experimental Therapeutics, 2Department of Pediatric Oncology/Hematology, Ernst Moritz Arndt University, Greifswald, Germany; and
- 3Department of Pharmacology-Oncology, Altana Pharma AG, Konstanz, Germany
- Requests for reprints: James F. Beck, Zentrum für Kinder- und Jugendmedizin, Abteilung für Pädiatrische Onkologie und Hämatologie, Soldmannstraße 15, D-17487 Greifswald, Germany. Phone: 49-3834-866324; Fax: 49-3834-866323. E-mail: beck{at}uni-greifswald.de
Abstract
Tumor necrosis factor–related apoptosis-inducing ligand (TRAIL) is a highly promising candidate for the treatment of cancer because it elicits cell death in the majority of tumor cells while sparing most normal cells. Some cancers, however, display resistance to TRAIL, suggesting that treatment with TRAIL alone may be insufficient for cancer therapy. In the present study, we explored whether the apoptotic responsiveness of PC-3 prostate cancer cells to TRAIL could be enhanced by targeting the novel protein kinase C (PKC) isoform η. Transfection of PC-3 cells with second-generation chimeric antisense oligonucleotides against PKCη caused a time- and dose-dependent knockdown of PKCη, as revealed by real-time RT-PCR and Western blot analyses. Knockdown of PKCη resulted in a marked amplification of TRAIL's cytotoxic activity. Cell killing could be substantially prevented by the pan-caspase inhibitor z-VAD-fmk. In addition, PKCη knockdown and administration of TRAIL significantly synergized in activation of caspase-3 and internucleosomal DNA fragmentation. Knockdown of PKCη augmented TRAIL-induced dissipation of the mitochondrial transmembrane potential and release of cytochrome c from mitochondria into the cytosol, indicating that PKCη acts upstream of mitochondria. We conclude that PKCη represents a considerable resistance factor with respect to TRAIL and a promising target to exploit the therapeutic potential of TRAIL.
Footnotes
-
Grant support: “Wilhelm Sander-Stiftung, Neustadt/Donau” and by the German Federal Ministry for Education and Research (NBL3 program, reference 01 ZZ 0103).
-
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
-
- Accepted May 11, 2004.
- Received February 27, 2004.
- Revision received May 3, 2004.
- American Association for Cancer Research










